ABSTRACT
Filamentous fungi are rich source of production of medicinal compounds at the industrial level as high levels of proteins and metabolites secreted by fungi in their culture medium possess efficient biomedical properties. Fungal species generally possess specific biomedical activities, however, out of a total 1.5 million only ~1,800 fungal species are described to have biomedical activities and prospects to explore new compounds for new biomedical and industrial applications. Initially, filamentous fungi (e.g., Trichoderma, Aspergillus, Rhizopus, and Penicillium species) were explored for their extraordinary extracellular enzyme synthesis mechanisms and protein secretion machinery for producing single cell proteins for large scale industrial production. Recent developments in the fields of genomics and proteomics offers new opportunities to biotechnologists to combine all the information to extend the bio-manufacturing of recombinant proteins of fungal origins in filamentous fungi. This can be achieved by facilitating filamentous fungi to express multiple proteins encoding genes and identifying new biosynthetic pathways to produce new proteins as well as secondary metabolites. 348Similarly, bacterial cells are also used as bio-factory to express proteins of fungal origin, this method reduces the time of production as compared to fungal method.
